BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34438237)

  • 1. Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis.
    Giustozzi M; Becattini C; Roila F; Agnelli G; Mandalà M
    Cancer Treat Rev; 2021 Nov; 100():102280. PubMed ID: 34438237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
    Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
    Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
    J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Yang M; Cao H; Wang C; Yu C; Sun P
    J Cancer Res Ther; 2024 Apr; 20(2):509-521. PubMed ID: 38687920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients.
    He X; Wei SN; Qin WW; Geng N; Li B; Song S; Wang P
    Expert Rev Hematol; 2023; 16(12):1135-1142. PubMed ID: 37883026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials.
    Ma Z; Sun X; Zhang Y; Li H; Sun D; An Z; Zhang Y
    Thromb Haemost; 2022 Oct; 122(10):1757-1766. PubMed ID: 35772727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
    Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Chen R; Hou X; Yang L; Zhao D
    Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review.
    Solinas C; Saba L; Sganzerla P; Petrelli F
    Thromb Res; 2020 Dec; 196():444-453. PubMed ID: 33065409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
    le Sève JD; Guédon AF; Bordenave S; Agard C; Connault J; Pistorius MA; Quéreux G; Espitia O
    Thromb Haemost; 2023 Nov; 123(11):1049-1056. PubMed ID: 37257835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between NSCLC Cells, CD8
    Freitas-Dias C; Gonçalves F; Martins F; Lemos I; Gonçalves LG; Serpa J
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
    Deschênes-Simard X; Richard C; Galland L; Blais F; Desilets A; Malo J; Cvetkovic L; Belkaid W; Elkrief A; Gagné A; Hamel MA; Orain M; Joubert P; Ghiringhelli F; Routy B; Blais N
    Thromb Res; 2021 Sep; 205():29-39. PubMed ID: 34246011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
    Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
    Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Yuan Y; Wan X; Yin D; Li R; Chen W; Suo C; Song H
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD011300. PubMed ID: 34870327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
    Qin Q; Wang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang H; Li X; Huang X; Li J; Ma H; Zeng R
    J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.